Cargando…

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

Pancreatic islet β-cell dysfunction is characterized by defective glucose-stimulated insulin secretion (GSIS) and is a predominant component of the pathophysiology of diabetes. Imeglimin, a novel first-in-class small molecule tetrahydrotriazine drug candidate, improves glycemia and GSIS in preclinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hallakou-Bozec, Sophie, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894908/ https://www.ncbi.nlm.nih.gov/pubmed/33606677 http://dx.doi.org/10.1371/journal.pone.0241651

Ejemplares similares

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
por: Theurey, Pierre, et al.
Publicado: (2022)

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity
por: Theurey, Pierre, et al.
Publicado: (2022)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
por: Detaille, D, et al.
Publicado: (2016)

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study
por: Fouqueray, Pascale, et al.
Publicado: (2021)

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells
por: Vial, Guillaume, et al.
Publicado: (2021)

Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome
por: Lachaux, Marianne, et al.
Publicado: (2020)

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
por: Jacques, Vincent, et al.
Publicado: (2021)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Effects of the anti-diabetic imeglimin in hyperglycemic mice with septic shock
por: Wagner, F, et al.
Publicado: (2012)

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis
por: Gluais‐Dagorn, Pascale, et al.
Publicado: (2021)

Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
por: Yaribeygi, Habib, et al.
Publicado: (2020)

Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period
por: Reilhac, Caroline, et al.
Publicado: (2022)

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes
por: Tomita, Yoshiko, et al.
Publicado: (2022)

Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Stimulatory effect of imeglimin on incretin secretion
por: Yingyue, Quan, et al.
Publicado: (2023)

Palmitate is not an effective fuel for pancreatic islets and amplifies insulin secretion independent of calcium release from endoplasmic reticulum
por: Kuok, Iok Teng, et al.
Publicado: (2019)

Current understanding of imeglimin action on pancreatic β‐cells: Involvement of mitochondria and endoplasmic reticulum homeostasis
por: Fauzi, Muhammad, et al.
Publicado: (2022)

A novel mechanism of imeglimin‐mediated insulin secretion via the cADPR‐TRP channel pathway
por: Funazaki, Shunsuke, et al.
Publicado: (2021)

Methylamine Activates Glucose Uptake in Human Adipocytes Without Overpassing Action of Insulin or Stimulating its Secretion in Pancreatic Islets
por: Carpéné, Christian, et al.
Publicado: (2019)

Menaquinone-4 Amplified Glucose-Stimulated Insulin Secretion in Isolated Mouse Pancreatic Islets and INS-1 Rat Insulinoma Cells
por: Ho, Hsin-Jung, et al.
Publicado: (2019)

Imeglimin‐mediated glycemic control in maternally inherited deafness and diabetes
por: Ishibashi, Ryoichi, et al.
Publicado: (2023)

Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules
por: Sanada, Junpei, et al.
Publicado: (2022)

Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes
por: Hozumi, Kaori, et al.
Publicado: (2023)

Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets
por: Dai, C., et al.
Publicado: (2011)

Experimental evaluation and computational modeling of the effects of encapsulation on the time-profile of glucose-stimulated insulin release of pancreatic islets
por: Buchwald, Peter, et al.
Publicado: (2015)

The Effects of Imeglimin on the Daily Glycemic Profile Evaluated by Intermittently Scanned Continuous Glucose Monitoring: Retrospective, Single-Center, Observational Study
por: Oda, Tomoyasu, et al.
Publicado: (2022)

Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes
por: Vuylsteke, Valerie, et al.
Publicado: (2015)

Development of Imeglimin Electrospun Nanofibers as a Potential Buccal Antidiabetic Therapeutic Approach
por: Alamer, Ali A., et al.
Publicado: (2023)

Letter to the Editor: Can Imeglimin Improve the Systolic Time Intervals in Diabetes Mellitus?
por: Nishikawa, Tomoaki, et al.
Publicado: (2023)

SNAP-25 is expressed in islets of Langerhans and is involved in insulin release
Publicado: (1995)

The role of beta cell heterogeneity in islet function and insulin release
por: Nasteska, Daniela, et al.
Publicado: (2018)

ADCY5 Couples Glucose to Insulin Secretion in Human Islets
por: Hodson, David J., et al.
Publicado: (2014)

Intra-islet glucagon secretion and action in the regulation of glucose homeostasis
por: Wang, Qinghua, et al.
Publicado: (2013)

Glutamate Acts as a Key Signal Linking Glucose Metabolism to Incretin/cAMP Action to Amplify Insulin Secretion
por: Gheni, Ghupurjan, et al.
Publicado: (2014)

Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study
por: Uchida, Taisuke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_50adr120dc8mim1ud9febhrf7o